Is SGMO or MTVA more profitable?

MetaVia has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. MetaVia's return on equity of -209.67% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% MetaVia N/A -209.67% -107.91%

Do analysts recommend MTVA or BCTX?

MetaVia presently has a consensus target price of $20.00, suggesting a potential upside of 1,242.28%. Given MetaVia's stronger consensus rating and higher possible upside, analysts plainly believe MetaVia is more favorable than Briacell Therap. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Briacell Therap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, MTVA or BCTX?

MetaVia is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Briacell Therap N/A N/A -$26.31M -$7.92 N/A

Is MTVA or BCTX more profitable?

Briacell Therap's return on equity of -153.53% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Briacell Therap N/A -153.53% -129.26%

Which has preferable valuation & earnings, MTVA or QNCX?

MetaVia is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MetaVia N/A N/A -$12.97M -$3.23 N/A Quince Therapeutics N/A N/A -$83.98M -$212.40 N/A

Is MTVA or QNCX more profitable?

Quince Therapeutics' return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Quince Therapeutics N/A N/A -67.99%

Does the media refer more to MTVA or QNCX?

In the previous week, MetaVia had 7 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for MetaVia and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat MetaVia's score of 0.46 indicating that Quince Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quince Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, KYNB or MTVA?

Kyntra Bio has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyntra Bio $6.44M 4.43 $183.45M $40.46 0.17 MetaVia N/A N/A -$12.97M -$3.23 N/A

Is KYNB or MTVA more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to MetaVia's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Kyntra Bio 2,199.13% N/A -45.24% MetaVia N/A -209.67% -107.91%

Does the media prefer KYNB or MTVA?

In the previous week, MetaVia had 6 more articles in the media than Kyntra Bio. MarketBeat recorded 11 mentions for MetaVia and 5 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.55 beat MetaVia's score of 0.46 indicating that Kyntra Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MetaVia 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, TVGN or MTVA?

Tevogen Bio is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tevogen Bio N/A N/A -$26.27M -$4.61 N/A MetaVia N/A N/A -$12.97M -$3.23 N/A

Is TVGN or MTVA more profitable?

Tevogen Bio's return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets Tevogen Bio N/A N/A -472.77% MetaVia N/A -209.67% -107.91%

MetaVia (MTVA) Competitors

$1.49 +0.03 (+2.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.51 +0.02 (+1.34%)

As of 07:05 PM Eastern

Compare

MTVA vs. SGMO, BCTX, QNCX, KYNB, and TVGN

Should you buy MetaVia stock or one of its competitors? MetaVia's main competitors and comparable companies include Sangamo Therapeutics (SGMO), Briacell Therap (BCTX), Quince Therapeutics (QNCX), Kyntra Bio (KYNB), and Tevogen Bio (TVGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MetaVia compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

In the previous week, MetaVia had 11 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 11 mentions for MetaVia and 0 mentions for Sangamo Therapeutics. MetaVia's average media sentiment score of 0.46 beat Sangamo Therapeutics' score of 0.00 indicating that MetaVia is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
MetaVia	Neutral

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of MetaVia shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 0.6% of MetaVia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

MetaVia has lower revenue, but higher earnings than Sangamo Therapeutics. MetaVia is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Sangamo Therapeutics currently has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. MetaVia has a consensus price target of $20.00, indicating a potential upside of 1,242.28%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

MetaVia has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. MetaVia's return on equity of -209.67% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
MetaVia	N/A	-209.67%	-107.91%

Summary

Sangamo Therapeutics and MetaVia tied by winning 7 of the 14 factors compared between the two stocks.

How does MetaVia compare to Briacell Therap?

MetaVia (NASDAQ:MTVA) and Briacell Therap (NASDAQ:BCTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

In the previous week, MetaVia had 10 more articles in the media than Briacell Therap. MarketBeat recorded 11 mentions for MetaVia and 1 mentions for Briacell Therap. Briacell Therap's average media sentiment score of 1.87 beat MetaVia's score of 0.46 indicating that Briacell Therap is being referred to more favorably in the news media.

Company	Overall Sentiment
MetaVia	Neutral
Briacell Therap	Very Positive

MetaVia has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Briacell Therap has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

Briacell Therap's return on equity of -153.53% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Briacell Therap	N/A	-153.53%	-129.26%

MetaVia is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Briacell Therap	N/A	N/A	-$26.31M	-$7.92	N/A

1.4% of MetaVia shares are held by institutional investors. Comparatively, 15.4% of Briacell Therap shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Comparatively, 0.7% of Briacell Therap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MetaVia presently has a consensus target price of $20.00, suggesting a potential upside of 1,242.28%. Given MetaVia's stronger consensus rating and higher possible upside, analysts plainly believe MetaVia is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MetaVia beats Briacell Therap on 7 of the 13 factors compared between the two stocks.

How does MetaVia compare to Quince Therapeutics?

MetaVia (NASDAQ:MTVA) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

MetaVia has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

In the previous week, MetaVia had 7 more articles in the media than Quince Therapeutics. MarketBeat recorded 11 mentions for MetaVia and 4 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.94 beat MetaVia's score of 0.46 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quince Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Quince Therapeutics	N/A	N/A	-67.99%

1.4% of MetaVia shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 0.6% of MetaVia shares are held by insiders. Comparatively, 7.1% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MetaVia currently has a consensus price target of $20.00, suggesting a potential upside of 1,242.28%. Quince Therapeutics has a consensus price target of $310.50, suggesting a potential upside of 812.16%. Given MetaVia's higher possible upside, equities analysts clearly believe MetaVia is more favorable than Quince Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.27

MetaVia is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Quince Therapeutics	N/A	N/A	-$83.98M	-$212.40	N/A

Summary

Quince Therapeutics beats MetaVia on 10 of the 14 factors compared between the two stocks.

How does MetaVia compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Kyntra Bio has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market. Comparatively, MetaVia has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Kyntra Bio has a net margin of 2,199.13% compared to MetaVia's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-45.24%
MetaVia	N/A	-209.67%	-107.91%

Kyntra Bio has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	4.43	$183.45M	$40.46	0.17
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Kyntra Bio currently has a consensus target price of $32.50, suggesting a potential upside of 360.99%. MetaVia has a consensus target price of $20.00, suggesting a potential upside of 1,242.28%. Given MetaVia's higher possible upside, analysts plainly believe MetaVia is more favorable than Kyntra Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 0.6% of MetaVia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, MetaVia had 6 more articles in the media than Kyntra Bio. MarketBeat recorded 11 mentions for MetaVia and 5 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 0.55 beat MetaVia's score of 0.46 indicating that Kyntra Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MetaVia	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kyntra Bio beats MetaVia on 14 of the 16 factors compared between the two stocks.

How does MetaVia compare to Tevogen Bio?

Tevogen Bio (NASDAQ:TVGN) and MetaVia (NASDAQ:MTVA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

1.4% of MetaVia shares are owned by institutional investors. 65.6% of Tevogen Bio shares are owned by company insiders. Comparatively, 0.6% of MetaVia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, MetaVia had 9 more articles in the media than Tevogen Bio. MarketBeat recorded 11 mentions for MetaVia and 2 mentions for Tevogen Bio. Tevogen Bio's average media sentiment score of 1.87 beat MetaVia's score of 0.46 indicating that Tevogen Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Tevogen Bio	Very Positive
MetaVia	Neutral

Tevogen Bio has a beta of 0.18, meaning that its share price is 82% less volatile than the broader market. Comparatively, MetaVia has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Tevogen Bio currently has a consensus target price of $100.00, indicating a potential upside of 1,355.60%. MetaVia has a consensus target price of $20.00, indicating a potential upside of 1,242.28%. Given Tevogen Bio's higher probable upside, equities analysts plainly believe Tevogen Bio is more favorable than MetaVia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tevogen Bio's return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tevogen Bio	N/A	N/A	-472.77%
MetaVia	N/A	-209.67%	-107.91%

Tevogen Bio is trading at a lower price-to-earnings ratio than MetaVia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tevogen Bio	N/A	N/A	-$26.27M	-$4.61	N/A
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A

Summary

MetaVia beats Tevogen Bio on 9 of the 13 factors compared between the two stocks.

Get MetaVia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MTVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MTVA vs. The Competition

Export

Metric	MetaVia	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.54M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-0.46	6.29	211.09	21.74
Price / Sales	N/A	1,295.89	602.98	92.99
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	1.13	16.78	12.91	6.24
Net Income	-$12.97M	-$13.32M	$3.45B	$347.60M
7 Day Performance	N/A	1.74%	1.12%	1.07%
1 Month Performance	-22.80%	1.60%	1.79%	1.03%
1 Year Performance	-78.84%	56.43%	67.69%	20.77%

MetaVia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MTVA MetaVia	2.56 of 5 stars	$1.49 +2.1%	$20.00 +1,242.3%	-79.3%	$7.54M	N/A	N/A	8	News Coverage Short Interest Decrease Analyst Revision
SGMO Sangamo Therapeutics	0.9503 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
BCTX Briacell Therap	0.9597 of 5 stars	$3.51 +0.3%	N/A	-52.5%	$30.54M	N/A	N/A	8	Positive News
QNCX Quince Therapeutics	2.9895 of 5 stars	$29.75 +3.0%	$568.40 +1,810.7%	-90.6%	$30.09M	N/A	N/A	60	News Coverage Earnings Report Analyst Upgrade
KYNB Kyntra Bio	2.5584 of 5 stars	$7.03 +0.6%	$32.50 +362.3%	N/A	$28.46M	$7.44M	0.17	570	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MTVA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetaVia (MTVA) Competitors

MTVA vs. SGMO, BCTX, QNCX, KYNB, and TVGN

How does MetaVia compare to Sangamo Therapeutics?

Summary

How does MetaVia compare to Briacell Therap?

Summary

How does MetaVia compare to Quince Therapeutics?

Summary

How does MetaVia compare to Kyntra Bio?

Summary

How does MetaVia compare to Tevogen Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MetaVia (MTVA) Competitors

MTVA vs. SGMO, BCTX, QNCX, KYNB, and TVGN

How does MetaVia compare to Sangamo Therapeutics?

Does the media prefer SGMO or MTVA?

Do institutionals and insiders have more ownership in SGMO or MTVA?

Which has preferable earnings and valuation, SGMO or MTVA?

Do analysts rate SGMO or MTVA?

Which has more risk & volatility, SGMO or MTVA?

Is SGMO or MTVA more profitable?

Summary

How does MetaVia compare to Briacell Therap?

Does the media refer more to MTVA or BCTX?

Which has more volatility and risk, MTVA or BCTX?

Is MTVA or BCTX more profitable?

Which has stronger earnings & valuation, MTVA or BCTX?

Do institutionals and insiders have more ownership in MTVA or BCTX?

Do analysts recommend MTVA or BCTX?

Summary

How does MetaVia compare to Quince Therapeutics?

Which has more risk and volatility, MTVA or QNCX?

Does the media refer more to MTVA or QNCX?

Is MTVA or QNCX more profitable?

Do insiders & institutionals have more ownership in MTVA or QNCX?

Do analysts recommend MTVA or QNCX?

Which has preferable valuation & earnings, MTVA or QNCX?

Summary

How does MetaVia compare to Kyntra Bio?

Which has more volatility and risk, KYNB or MTVA?

Is KYNB or MTVA more profitable?

Which has stronger earnings and valuation, KYNB or MTVA?

Do analysts rate KYNB or MTVA?

Do institutionals & insiders believe in KYNB or MTVA?

Does the media prefer KYNB or MTVA?

Summary

How does MetaVia compare to Tevogen Bio?

Do insiders and institutionals believe in TVGN or MTVA?

Does the media prefer TVGN or MTVA?

Which has more risk and volatility, TVGN or MTVA?

Do analysts rate TVGN or MTVA?

Is TVGN or MTVA more profitable?

Which has higher earnings & valuation, TVGN or MTVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTVA vs. The Competition

MetaVia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools